- Mitsubishi Chemical keeps its full-year operating income prediction at 210.00 billion yen, lower than the estimated 242.2 billion yen.
- Full-year net income forecast remains at 52.00 billion yen, missing the estimate of 70.75 billion yen.
- Full-year net sales projection is maintained at 4.62 trillion yen, slightly below the estimate of 4.63 trillion yen.
- Dividend per share remains unchanged at 32.00 yen, matching the estimate.
- For the first half of the year, the company expects an operating income of 84.00 billion yen.
- First half net income is forecasted at 10.00 billion yen.
- Net sales for the first half of the year are expected to reach 2.25 trillion yen.
- Analyst recommendations include 7 buys, 4 holds, and 0 sells.
- The comparisons are based on values reported by the company’s original disclosures.
A look at Mitsubishi Chemical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 5 | |
| Growth | 5 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 4.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Mitsubishi Chemical Holding Corporation is looking at a positive long-term outlook. With top scores in Value, Dividend, and Growth categories, the company shows strong fundamentals and potential for future growth. The high scores in these areas indicate a solid financial position, consistent dividend payments, and promising growth prospects for investors.
However, the company’s lower scores in Resilience and Momentum suggest some areas of caution. While the company may face challenges in terms of resilience to market disruptions and may lack strong short-term momentum, the overall picture remains optimistic due to its strong performance in key fundamental areas. Mitsubishi Chemical, as a holding company managing its subsidiaries, seems well-positioned for long-term success and value creation for investors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
